Jun Zhou

Dr. Jun Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
JTJunyue Tao
Junyue Tao
XLXiao Li
Xiao Li
CLChaozhao Liang
Chaozhao Liang
YLYi Liu
Yi Liu
JZJun Zhou
Jun Zhou
Background: Clear cell renal cell carcinoma (ccRCC) is a malignant tumor with limited treatment options. A recent study confirmed the involvement of basement membrane (BM) genes in the progression of many cancers. Therefore, we studied the role and prognostic significance of BM genes in ccRCC.Methods: Co-expression analysis of ccRCC-related information deposited in The Cancer Genome Atlas database and a BM geneset from a recent study was conducted. The differentially expressed BM genes were validated using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Least absolute shrinkage and selection operator regression and univariate Cox regression analyses were performed to identify a BM gene signature with prognostic significance for ccRCC. Multivariate Cox regression, time-dependent receiver operating characteristic, Kaplan–Meier, and nomogram analyses were implemented to appraise the prognostic ability of the signature and the findings were further verified using a Gene Expression Omnibus dataset. Additionally, immune cell infiltration and and pathway enrichment analyses were performed using ImmuCellAI and Gene Set Enrichment Analysis (GSEA), respectively. Finally, the DSIGDB dataset was used to screen small-molecule therapeutic drugs that may be useful in treating ccRCC patients.Results: We identified 108 BM genes exhibiting different expression levels compared to that in normal kidney tissues, among which 32 genes had prognostic values. The qRT-PCR analyses confirmed that the expression patterns of four of the ten selected genes were the same as the predicted ones. Additionally, we successfully established and validated a ccRCC patient prediction model based on 16 BM genes and observed that the model function is an independent predictor. GSEA revealed that differentially expressed BM genes mainly displayed significant enrichment of tumor and metabolic signaling cascades. The BM gene signature was also associated with immune cell infiltration and checkpoints. Eight small-molecule drugs may have therapeutic effects on ccRCC patients.Conclusion: This study explored the function of BM genes in ccRCC for the first time. Reliable prognostic biomarkers that affect the survival of ccRCC patients were determined, and a BM gene-based prognostic model was established.

10 October 2024 in Materials Today Bio
Verified
Journal Article
Open access
WWWeibo Wang
Weibo Wang
STSupeng Tai
Supeng Tai
JTJunyue Tao
Junyue Tao
LYLexing Yang
Lexing Yang
XCXi Cheng
Xi Cheng
JZJun Zhou
Jun Zhou
Ischemia-reperfusion injury (IRI) commonly occurs in clinical settings, particularly in medical practices such as organ transplantation, cardiopulmonary resuscitation, and recovery from acute trauma, posing substantial challenges in clinical therapies. Current systemic therapies for IRI are limited by poor drug targeting, short efficacy, and significant side effects. Owing to their exceptional biocompatibility, biodegradability, excellent mechanical properties, targeting capabilities, controlled release potential, and properties mimicking the extracellular matrix (ECM), hydrogels not only serve as superior platforms for therapeutic substance delivery and retention, but also facilitate bioenvironment cultivation and cell recruitment, demonstrating significant potential in IRI treatment. This review explores the pathological processes of IRI and discusses the roles and therapeutic outcomes of various hydrogel systems. By categorizing hydrogel systems into depots delivering therapeutic agents, scaffolds encapsulating mesenchymal stem cells (MSCs), and ECM-mimicking hydrogels, this article emphasizes the selection of polymers and therapeutic substances, and details special crosslinking mechanisms and physicochemical properties, as well as summarizes the application of hydrogel systems for IRI treatment. Furthermore, it evaluates the limitations of current hydrogel treatments and suggests directions for future clinical applications.

11 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JTJunyue Tao
Junyue Tao
YCYiding Chen
Yiding Chen
XBXiaokang Bian
Xiaokang Bian
TCTingting Cai
Tingting Cai
CSChanghao Song
Changhao Song
JZJun Zhou
Jun Zhou
Background: Recent studies have underscored the potential involvement of cathepsin Z (CTSZ) in modulating the progression of diverse tumor types. Nevertheless, its specific role in prostate cancer (PCa) remains insufficiently understood. This study aimed to investigate the expression profile of CTSZ in PCa and evaluate its prognostic significance.Methods: Three independent cohorts, including TCGA-PRAD, MSKCC, and a real-world AHMU-PC cohort were enrolled in this study. Multidimensional strategies consist of spatial transcriptome analysis, differential expression analysis, survival analysis, and correlation with clinicopathological features were performed. Immunohistochemical staining and multiplex immunofluorescence staining were performed to evaluate the expression and spatial distribution of CTSZ and immune-related markers in PCa tissues. Functional studies were conducted through a series of experiments, including CCK-8 assay, colony formation, wound healing, and Transwell migration assays. ssGSEA and CIBERSORT algorithms immune infiltration evaluation, and GISTIC2.0 and MutSigCV for tumor mutation burden. Gene Set Enrichment Analysis was performed to identify potential signaling pathways involved.Results: CTSZ is highly expressed in PCa tissues and is associated with higher Gleason scores, advanced T/N staging, and poor prognosis. Survival analyses across multiple cohorts indicate that high CTSZ expression predicts shorter progression-free survival and overall survival. In vitro experiments showed that CTSZ knockdown suppresses PCa cell proliferation, invasion, migration, and colony formation. Immune profiling revealed that high-CTSZ tumors exhibit an immune-enriched microenvironment, characterized by increased infiltration of regulatory T cells and M2 macrophages, suggesting an immunosuppressive state. Notably, despite this phenotype, PD-1 and PD-L1 levels were also elevated in high-CTSZ tumors, indicating a potential role in immune checkpoint regulation. Additionally, high CTSZ expression was correlated with increased tumor mutation burden, particularly enriched for TP53 and SPOP mutations. GSEA identified CAM, VEGF, and STAT signaling pathways as potential mechanisms through which CTSZ promotes tumor progression, highlighting its potential as both a prognostic biomarker and therapeutic target in PCa.Conclusions: Our study highlights CTSZ as a potential prognostic and therapeutic biomarker in PCa, demonstrating that its overexpression is associated with immune cell infiltration, immune checkpoint molecule expression (such as PD-1 and PD-L1), tumor mutation burden, and key oncogenic pathways. These findings suggest that CTSZ may serve not only as a predictor of patient prognosis but also as a promising indicator for immunotherapy response and personalized treatment strategies in PCa.

27 April 2023 in BMC Urology
Verified
Journal Article
Open access
PDF file
JTJunyue Tao
Junyue Tao
QGQintao Ge
Qintao Ge
JMJialing Meng
Jialing Meng
CLChaozhao Liang
Chaozhao Liang
ZHZongyao Hao
Zongyao Hao
JZJun Zhou
Jun Zhou
Background: There is increasing evidence that DEAD-box helicases (DDX) can act either as promoters or suppressors in various cancer types. Nevertheless, the function of DDX49 in prostate cancer (PCa) is unknown. This study reveals the prognostic and predictive value of DDX49 in PCa. Methods: First, we evaluated the expression of DDX49 between PCa and normal tissues based on TCGA and GEO databases. Univariate and multivariate regression analyses were conducted to reveal the risk factors for PCa recurrence. A K–M curve was employed to assess the relationship between DDX49 and recurrence-free survival. In vitro, DDX49 expression was evaluated in PCa and normal prostate cell lines. Furthermore, we constructed a shDDX49 lentivirus to knock down the expression of DDX49. Celigo® Image Cytometer and MTT assay were performed to analyse cell proliferation in PC-3 cells. Cell cycle distribution was detected with flow cytometry analysis. Apoptosis affected by the lack of DDX49 was metred with the PathScan® Stress and Apoptosis Signalling Antibody Array Kit. Results: This study shows a high increase in DDX49 in PCa tissues in comparison with normal tissues and that increased DDX49 indicates a poor prognosis among PCa patients. Meanwhile, DDX49 knockdown suppressed the proliferation and migration of PC-3 cells, causing cell cycle arrest in the G1 phase. Stress and apoptosis pathway analysis revealed that the phosphorylation of HSP27, p53, and SAPK/JNK was reduced in the DDX49 knockdown group compared with the control group. Conclusions: In summary, these results suggest that high expression of DDX49 predicts a poor prognosis among PCa patients. Downregulation of DDX49 can suppress cell proliferation, block the cell cycle, and facilitate cell apoptosis. Therefore, knockdown of DDX49 is a promising novel therapy for treating patients with PCa.

2 December 2022 in Medicine
Verified
Journal Article
Open access
JTJunyue Tao
Junyue Tao
HYHao Yang
Hao Yang
ZHZongyao Hao
Zongyao Hao
CLChaozhao Liang
Chaozhao Liang
YDYingying Du
Yingying Du
JZJun Zhou
Jun Zhou
Rationale: Renal clear cell sarcoma is a rare and highly invasive malignant renal tumor that easily relapses after treatment. Recurrent recurrent clear cell carcinoma (CCSK) responds poorly to chemotherapy and has no established standardized treatment, and need to be explored potentially useful treatments. Patient concerns: A 18-years-old patient with renal clear cell sarcoma recurrence after open radical nephrectomy. Diagnosis: Recurrent clear cell sarcoma. Interventions: After chemotherapy alone failed, the patient received 6 courses of anlotinib combined with chemotherapy. The tumor had significantly reduced in size and the recurrent tumor and part of the liver were resected. Outcomes: No tumor recurrence or metastasis was detected during the follow-up 8 months after the operation. Lessons: This is the first report describing the use of anlotinib in treating CCSK. We believe that anlotinib combined with chemotherapy may be a useful treatment option for patients with recurrent CCSK.

23 November 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
XXXiao Xiao
Xiao Xiao
JZJun Zhou
Jun Zhou
MFMeng Fang
Meng Fang
JJJun Ji
Jun Ji
CHChenjun Huang
Chenjun Huang
CGChun-Fang Gao
Chun-Fang Gao
Objective: Biliary tract cancer (BTC) is a rare malignancy and lack of effective diagnostic and prognostic marker. Here, we aimed to investigate the clinical implication of TP53 mutation detection in BTC using droplet digital PCR (ddPCR).Methods: TP53 gene (loci p.R175H, p.R248Q, p.R248W, and p.R273H) mutation frequencies of 45 pairs of tumor tissues (TTs) and adjacent normal tissues (ANTTs) were analyzed, respectively, using ddPCR. Meanwhile, the same detections were conducted in plasma cell‐free DNA (cfNDA) of 156 subjects including BTC, disease control (DC), and healthy controls (HC). The logistic regression algorithm was established to identify BTC. The correlations between mutations and clinicopathological features as well as the effects of TP53 mutation frequency on BTC prognosis were assessed.Results: The higher mutation of p.R175H was found in TTs compared with ANTT (p = 0.006). The mutation at p.R273H in cfDNA was also higher in BTC when compared with DC and HC (p < 0.05). The logistic algorithms combining p.R273H mutation demonstrated the higher diagnostic efficacy trend than carbohydrate antigen 19–9 (CA19‐9), carcinoembryonic antigen (CEA), and alpha‐fetoprotein (AFP) in identifying BTC from DC (the area under the curves of the algorithm: 0.845, 95% CI:0.775–0.914). The median overall survival (OS) and progression‐free survival (PFS) were significantly shorter when the BTC patients harboring the p.R273H mutation (OS: p = 0.032; PFS: p = 0.046).Conclusion: This study revealed for the first time that the quantitative TP53 mutations using the ddPCR might serve as a potential genetic biomarker for BTC diagnosis and prognosis assessment.